5271results about "Genetic engineering" patented technology

The invention discloses a biosynthesis system for high-yield 1, 6-hexamethylenediamine and application of the biosynthesis system, and belongs to the technical field of biology. According to the method, key genes which are excavated and optimized in a 1, 6-hexamethylenediamine biosynthetic pathway are co-expressed in a single cell module or a multi-cell module, and different enzyme elements expressed by the cell module are subjected to enzyme cascade reaction, so that 1, 6-hexamethylenediamine can be efficiently synthesized by taking caprolactam or 6-aminocaproic acid as a substrate; furthermore, after the carboxylic acid reductase MaCAR is mutated, the catalytic activity of the carboxylic acid reductase MaCAR can be remarkably improved, and the yield of the 1, 6-hexamethylenediamine is further improved; in addition, the biosynthesis system disclosed by the invention directly takes the cell module as a whole-cell catalyst, and an enzyme purification step is avoided, so that the biosynthesis system has the advantage of low cost.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to an SCRE10 gene for improving rice disease resistance and application of the SCRE10 gene, the base sequence of the SCRE10 gene is shown as SEQ ID NO.1, and the amino acid sequence of the SCRE10 gene is shown as SEQ ID NO.2. Through construction of a dexamethasone induced expression SCRE10 transgenic rice plant, it is found that the transgenic rice can significantly induce PR gene expression and active oxygen outbreak, and the resistance of rice to false smut and bacterial leaf blight can be improved. The invention proves that heterologous inducible expression of the Ustilaginoidea virens SCRE10 gene has the function of positively regulating the disease resistance of the rice, and the SCRE10 gene can be used for improving the disease resistance of the rice, which is of great significance to the creation of disease-resistant germplasm of the rice.

This invention provides a humanized monoclonal antibody that binds to advanced glycation end product (AGE) modified proteins or peptides on a cellular surface. [Solution] A humanized monoclonal antibody for advanced glycation end products, comprising at least one amino acid sequence selected from a group consisting of eight specific amino acid sequences, each with a different sequence. The antibody may be bound to a carboxymethyllysine-modified protein or peptide on a cell. The antibody can be used in a cell separation process, for example, in magnetic cell separation.

The invention belongs to the technical field of microbial genetic engineering, and particularly relates to an alpha-2, 3-sialyltransferase mutant and application thereof. The a-2, 3-sialyltransferase mutants V175N, P198A, G173D, D174Q, F196K and A315H are obtained by performing site-specific mutagenesis on six amino acids in an a-2, 3-sialyltransferase amino acid sequence coded by a gene derived from Campylobacter jejuni (OH4384), the yield of 3 '-sialyllactose is remarkably increased by single-point mutagenesis of the V175N, the yield of 3'-sialyllactose is remarkably increased by single-point mutagenesis of the V175N, the yield of 3 '-sialyllactose is remarkably increased by single-point mutagenesis of the P198A, the G173D, the D174Q, the F196K and the A315H, the optimal recombinant microbial strain 3 '-SL-09 (V175N / P198A / D174Q) is obtained through combination of multiple mutation sites, the yield can reach 5.91 g / L, the bottleneck problem of low catalytic efficiency of sialyltransferase is effectively solved, and an enzyme element with excellent performance is provided for high-efficiency and low-cost biological manufacturing of 3'-SL.

To provide a pharmaceutical composition for treating a cancer patient having a tumor having a total passenger gene mutation amount larger than the background mutation amount of the tumor.SOLUTION: A pharmaceutical composition for treating a subject having a tumor with a total passenger gene mutation load that is greater than the background mutation load of the tumor, wherein the background mutation load has been determined based on randomly selected genes of the tumor, comprising antibodies that bind to PD1 as an active ingredient. Antibodies that bind PD1 comprise a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 21 and / or comprise a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 22.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of molecular biology and genetic engineering, and particularly relates to a passion fruit PeDREB1 gene and application thereof in regulating temperature and drought stress tolerance. By overexpressing the passion fruit PeDREB1 transcription factor in the plant, the tolerance of the transgenic plant to temperature stress (low temperature and high temperature) and drought stress can be obviously enhanced, the growth recovery capability of the transgenic arabidopsis thaliana overexpressed with PeDREB1 after low temperature stress is obviously superior to that of a wild type, and the leaf area growth rate is increased by about 0.45-2.28%; under the condition that 0.2 mol / L to 0.3 mol / L mannitol simulates drought stress, the seed germination rate is increased by 5.39 percent to 9.29 percent, and the root length growth rate is increased by 1.08 percent to 6.72 percent; the invention provides a clear gene target and a directly applicable molecular resource for plant stress resistance molecular breeding, can provide theoretical support for subsequent clarification of a regulation mechanism of plant response temperature and drought stress, and also lays a foundation for plant stress resistance genetic improvement and new germplasm creation.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-6 protein and application. The combination comprises monoclonal antibodies 3A10 and 2G1, and amino acid sequences of complementary determining regions of variable regions of light and heavy chains of the monoclonal antibodies 3A10 and 2G1 are respectively shown as SEQ ID NO.1-12. The invention defines a complete variable region sequence and a coding nucleotide sequence of the antibody. The combination specifically recognizes human IL-6 recombinant and natural proteins, and has no cross reaction with IL-11. A double-antibody sandwich ELISA kit constructed based on the combination takes 3A10 as a coating antibody and 2G1 as a labeled antibody, and has high sensitivity and high specificity. The problems that an existing reagent is insufficient in specificity and low in sensitivity are solved, a reliable core raw material is provided for IL-6 standardized detection, and the method is suitable for preparation of a kit, a test strip and an antibody chip.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody pair for detecting feline immunodeficiency virus p24 protein and application thereof. The monoclonal antibody pair is monoclonal antibody 1D8 and monoclonal antibody 1H10, which can specifically recognize feline immunodeficiency virus p24 protein, and the heavy chain and light chain variable region complementarity determining region sequences of 1D8 and 1H10 are clear, and are respectively shown as SEQ ID NO. 1-12. The antibody pair can effectively avoid cross reaction, and significantly improve the accuracy and sensitivity of detection; the colloidal gold detection test strip constructed based on the antibody pair is simple and fast in operation, is suitable for early antigen detection of FIV infection, solves the problem that existing antibody detection cannot distinguish natural infection and vaccine immunization, and provides a reliable technical means for on-site screening and disease prevention and control of FIV.

The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

The invention relates to the field of rice gene engineering, and discloses an application of a GSE3.1 protein and a coding gene thereof in regulating and controlling the grain length, the grain width and the grain weight of rice seeds. According to the invention, a GSE3.1 gene is edited based on a CRISPR / Cas9 technology, a japonica rice variety Zhonghua 11 (ZH11) is introduced by using an agrobacterium-mediated method, and a knockout mutant is obtained through screening. The homozygous knockout mutation of the GSE3.1 gene in the invention leads to reduction of the grain width and grain length of rice seeds and reduction of thousand grain weight. According to the invention, the constructed plant overexpression vector ProActin: GSE3.1 is expressed in wild type ZH11, so that compared with the wild type plant, the seed grain length and grain width of the transgenic plant are obviously increased, and the thousand grain weight is obviously increased. Therefore, the GSE3.1 gene and the encoding protein thereof can regulate and control the size and the weight of the rice seeds, and are of great significance to cultivation of high-yield rice varieties.

The invention discloses application of an upstream non-coding region uORF of an ABA2 gene in regulation and control of crop agronomic traits, in particular to application in improvement of pre-harvest sprouting resistance of rice and cultivation of pre-harvest sprouting resistant rice strains, and belongs to the technical field of gene engineering. The invention finds that uORF in the upstream non-coding region of the crop ABA2 gene can inhibit the translation level of downstream ABA2 protein on the basis of not influencing the transcriptional level, so that the uORF can participate in regulation and control of crop agronomic traits in which ABA participates in regulation and control, such as improvement of pre-harvest sprouting resistance of rice. Therefore, the upstream non-coding region uORF of the crop ABA2 gene can be modified through a hybridization or gene editing technology, so that the purpose of regulating and controlling crop agronomic traits in which ABA participates in regulation and control is achieved, for example, site-directed mutagenesis is performed on an initiation codon of the upstream non-coding region uORF of the rice ABA2 gene, and the pre-harvest sprouting resistance of rice is improved.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The invention provides a group of monoclonal antibody pairs targeting adenovirus DBP protein, the monoclonal antibody pairs comprise a capture antibody and a detection antibody, each of the two antibodies comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, and the capture antibody and the detection antibody are used for capturing and detecting the adenovirus DBP protein. Wherein the capture antibody is a monoclonal antibody 19E3; and the detection antibody is selected from a monoclonal antibody 96 to 10D8, a monoclonal antibody 95 to 2B7, a monoclonal antibody 96 to 2C10, a monoclonal antibody 96 to 8E10, a monoclonal antibody 96 to 13D5 or a monoclonal antibody 96 to 2B10. The monoclonal antibody pair disclosed by the invention can be used for efficiently detecting various types of HAdV DBP.

The invention discloses a beta-amino acid dehydrogenase mutant and application of the beta-amino acid dehydrogenase mutant in preparation of (S)-3-aminobutyric acid. The beta-amino acid dehydrogenase mutant disclosed by the invention can be used for selectively reducing and aminating 3-oxobutyric acid to obtain (S)-3-aminobutyric acid, the substrate concentration can reach 20g / L, the conversion rate is greater than or equal to 99%, the ee value is greater than or equal to 99%, and the method is simple to operate and high in reaction efficiency and can be used for industrial production.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention relates to the technical field of biology, in particular to application of a biological product expressed by an EsPTI15 gene to regulation and control of tiller number. The nucleotide sequence of the EsPTI15 gene is shown as SEQ ID NO: 1, it is found for the first time that the tiller number of EsPTI15 gene overexpressed siberian wildrye is remarkably increased compared with wild siberian wildrye, and the result proves that overexpression of the EsPTI15 gene can positively regulate and control the plant tiller development process. The discovery not only enriches the molecular mechanism theory of plant tillering regulation, but also verifies that the EsPTI15 gene has the application potential of increasing the tillering number of the plant, and provides key theoretical support and gene resources for subsequent technical research and development of introducing the EsPTI15 gene through gene operation, increasing the tillering number of forage grass and further realizing biomass improvement.

The invention discloses an upland cotton GhCRK29 gene as well as an encoding protein and application thereof, the GhCRK29 gene is separated from cotton, the nucleotide sequence of the GhCRK29 gene is as shown in SEQ ID No.1, and the amino acid sequence of the encoding protein of the GhCRK29 gene is as shown in SEQ ID No.2. According to the invention, a virus-induced gene silencing technology and a transgenic overexpression technology are further utilized to carry out preliminary research on the function of the cotton GhCRK29 gene in cotton verticillium wilt resistance, and a result shows that the verticillium wilt resistance of a cotton seedling plant is obviously reduced after the GhCRK29 gene in cotton is silenced; after the GhCRK29 gene is over-expressed in arabidopsis thaliana or cotton, the verticillium wilt resistance of arabidopsis thaliana or cotton is remarkably improved, and the resistance of a GhCRK29 gene forward regulation plant to verticillium dahliae is determined; the invention has application prospects in the aspects of improving the verticillium wilt resistance of plants or cultivating verticillium wilt resistant plant varieties and the like.

The invention provides application of a TaNAC42 gene in regulation and control of wheat stem rust resistance, and belongs to the technical field of gene functions. It is found for the first time that the TaNAC42 gene of wheat is related to the wheat stem rust resistance, the TaNAC42 gene is induced to be silenced through viruses, the wheat stem rust resistance can be enhanced, wheat plants are easier to resist diseases, the TaNAC42 gene is over-expressed through the agrobacterium tumefaciens-mediated transient over-expression technology, the wheat stem rust resistance can be weakened, the wheat plants are more susceptible to diseases, and the wheat plants are more susceptible to diseases. Namely, the TaNAC42 gene can negatively participate in regulating and controlling the resistance of the wheat to the Puccinia graminicola, a new target gene is provided for improved breeding of wheat Puccinia graminicola resistance molecules, and the TaNAC42 gene has important utilization value in wheat production and breeding.

The invention discloses a recombinant protein for detecting a para-tumor Yo antibody through a CBA method and application, and belongs to the technical field of biomedical engineering.The amino acid sequence of the recombinant protein sequentially comprises a secretory signal peptide, a CDR2 protein partial sequence, a CDR2L protein partial sequence, a transmembrane region and a fluorescent label, and the secretory signal peptide is human albumin signal peptide ALB; the transmembrane region is a CD8a hinge; and the fluorescent label is mCherry. A novel recombinant protein which can be stably over-expressed on a cell membrane of an eukaryotic cell is constructed by intercepting specific partial sequences of CDR2 protein and CDR2L protein and redesigning and fusing a fluorescent label by using a secretory signal peptide, a transmembrane sequence and a connecting peptide, and the recombinant protein retains respective core antigen regions of the CDR2 protein and the CDR2L protein, so that the specific partial sequences of the CDR2 protein and the CDR2L protein can be stably over-expressed on the cell membrane of the eukaryotic cell. The kit can effectively overcome the defects in the aspects of sensitivity and specificity, and when a CBA method is adopted for detection, the detection rate of the para-tumor Yo antibody can be remarkably increased, and the false positive rate is reduced, so that the requirements of clinical detection are better met.

The invention discloses lysozyme, antibacterial peptide derived from the lysozyme and application of the lysozyme in preparation of antibacterial drugs. According to the invention, 1, 640 protein sequences recorded in a ruminant rumen caterpillars genome database are systematically predicted based on a lysozyme prediction model, and finally, the lysozyme with the amino acid sequence as shown in SEQ ID No.1 is relatively strong in antibacterial activity and stable in antibacterial activity, and is slightly influenced by environmental factors. According to the invention, an antibacterial peptide region of the lysozyme is analyzed and determined, three peptide fragments with clear antibacterial activity are identified, and the amino acid sequences of the peptide fragments are respectively shown as SEQ ID No.2, SEQ ID No.3 or SEQ ID No.4. The antibacterial peptide provided by the invention has relatively strong membrane destroying ability and broad-spectrum antibacterial activity, and compared with integral protein, the antibacterial peptide is simpler in structure and more flexible in synthesis and modification, and is easier to break through a bacterial drug-resistant mechanism.

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention discloses an EsSTB1 gene capable of increasing the number of branches of a plant, reducing the plant height and delaying flowering. The EsSTB1 gene has the functions of increasing the number of branches, reducing the plant height and delaying flowering, and a scientific basis and a new material are provided for cooperative regulation and control of tillering formation and reproductive growth of siberian wildrye; besides, the functional verification method of the EsSTB1 gene provided by the invention performs functional verification by applying transgenic arabidopsis thaliana starting from an internal regulation mechanism of tillering regulation of siberian wildrye, has obvious research depth and breadth and technical effects, and can obtain a plant strain with an intentional phenotype. Through verification, the siberian wildrye EsSTB1 gene disclosed by the invention can be used for remarkably increasing the number of branches of a plant, reducing the plant height and delaying flowering. The method is suitable for popularization and application in the biotechnology field.

The invention discloses a T-2 toxin monoclonal antibody and application thereof, and belongs to the technical field of biology. The monoclonal antibody contains a heavy chain variable region and a light chain variable region, the heavy chain variable region and the light chain variable region are both composed of complementary determining regions and frame regions, and the complementary determining regions are both composed of CDR1, CDR2 and CDR3. The monoclonal antibody can be used for preparing a T-2 toxin detection product. The T-2 toxin colloidal gold test strip provided by the invention has the characteristics of high sensitivity, good specificity and strong stability.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

The invention discloses an application of a rice yellow-like stripe protein gene OsYSL18. The sequence of the yellow-like stripe protein gene OsYSL18 is as shown in SEQ ID NO. 1. The gene can be applied in multiple aspects of preventing and controlling the cadmium element from being transferred to the overground part of the rice, reducing the cadmium content of rice grains and the like. The biological function of the yellow stripe-like protein gene OsYSL18 in rice is found through a large number of experiments, and after the gene is knocked out, the cadmium content of the overground part of a rice seedling subjected to cadmium treatment is remarkably reduced; after the rice is mature, the grain cadmium content is reduced by more than 85%.

The invention relates to antiviral application of a membrane fusion inhibition polypeptide. The membrane fusion inhibition polypeptide is used for treating diseases caused by virus infection of pneumoviridae.

The invention discloses an anti-SLC3A2 antibody or an antigen binding fragment thereof, the antibody comprises a heavy chain variable region and further comprises a light chain variable region, and the antibody specifically recognizes SLC3A2. Also disclosed are conjugates comprising an antibody against SLC3A2 or an antigen-binding fragment thereof, and the use of the antibodies of the disclosure in the treatment of disease.